Literature DB >> 18471791

Mechanisms of bone metastasis in prostate cancer: clinical implications.

Pavlos Msaouel1, Nikos Pissimissis, Antonios Halapas, Michael Koutsilieris.   

Abstract

Prostate cancer shows a strong predilection to spread to the bones. Once prostate tumour cells are engrafted in the skeleton, curative therapy is no longer possible and palliative treatment becomes the only option. Herein, we review the multifactorial mechanisms and complex cellular interactions that take place inside the bone metastatic microenvironment. Emphasis is given to the detection and treatment of the micrometastatic stage of prostate cancer, as well as our recent attempts to target the bone metastasis microenvironment-related survival factors using an anti-survival factor manipulation which can increase the efficacy of anticancer therapies such as androgen ablation therapy and chemotherapy in advanced prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18471791     DOI: 10.1016/j.beem.2008.01.011

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  35 in total

1.  Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis.

Authors:  Bhavani Krishnan; Thomas L Smith; Purnima Dubey; Michael E Zapadka; Frank M Torti; Mark C Willingham; E Ann Tallant; Patricia E Gallagher
Journal:  Prostate       Date:  2012-05-29       Impact factor: 4.104

2.  Role of hepcidin and iron metabolism in the onset of prostate cancer.

Authors:  Bin Zhao; Ruiqian Li; Gang Cheng; Zhiyao Li; Zhiping Zhang; Jun Li; Guoying Zhang; Chengwei Bi; Chen Hu; Libo Yang; Yonghong Lei; Qilin Wang
Journal:  Oncol Lett       Date:  2018-04-20       Impact factor: 2.967

Review 3.  Concise Review: Prostate Cancer Stem Cells: Current Understanding.

Authors:  Sergej Skvortsov; Ira-Ida Skvortsova; Dean G Tang; Anna Dubrovska
Journal:  Stem Cells       Date:  2018-08-27       Impact factor: 6.277

4.  Interleukin-6: a bone marrow stromal cell paracrine signal that induces neuroendocrine differentiation and modulates autophagy in bone metastatic PCa cells.

Authors:  Nikki A Delk; Mary C Farach-Carson
Journal:  Autophagy       Date:  2012-04-01       Impact factor: 16.016

5.  CXCL13 mediates prostate cancer cell proliferation through JNK signalling and invasion through ERK activation.

Authors:  C P El-Haibi; R Singh; P K Sharma; S Singh; J W Lillard
Journal:  Cell Prolif       Date:  2011-06-06       Impact factor: 6.831

6.  Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model.

Authors:  Peter Jantscheff; Vittorio Ziroli; Norbert Esser; Ralph Graeser; Jessica Kluth; Alena Sukolinskaya; Lenka A Taylor; Clemens Unger; Ulrich Massing
Journal:  Clin Exp Metastasis       Date:  2009-09-26       Impact factor: 5.150

Review 7.  Targeting tumor microenvironment with silibinin: promise and potential for a translational cancer chemopreventive strategy.

Authors:  Gagan Deep; Rajesh Agarwal
Journal:  Curr Cancer Drug Targets       Date:  2013-06       Impact factor: 3.428

8.  Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion.

Authors:  Fraser Conrad; Xiaodong Zhu; Xin Zhang; Robert J Chalkley; Alma L Burlingame; James D Marks; Bin Liu
Journal:  J Mol Med (Berl)       Date:  2009-02-14       Impact factor: 4.599

9.  Automated detection of sclerotic metastases in the thoracolumbar spine at CT.

Authors:  Joseph E Burns; Jianhua Yao; Tatjana S Wiese; Hector E Muñoz; Elizabeth C Jones; Ronald M Summers
Journal:  Radiology       Date:  2013-02-28       Impact factor: 11.105

Review 10.  Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance.

Authors:  Zacharoula Panteleakou; Peter Lembessis; Antigone Sourla; Nikolaos Pissimissis; Aristides Polyzos; Charalambos Deliveliotis; Michael Koutsilieris
Journal:  Mol Med       Date:  2008-12-03       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.